

ORCA - Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:https://orca.cardiff.ac.uk/id/eprint/125124/

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

 Luukkonen, Panu K., Nick, Auli, Hölttä-Vuori, Maarit, Thiele, Christoph, Isokuortti, Elina, Lallukka-Brück, Susanna, Zhou, You , Hakkarainen, Antti, Lundbom, Nina, Peltonen, Markku, Orho-Melander, Marju,
Oresic, Matej, Hyötyläinen, Tuulia, Hodson, Leanne, Ikonen, Elina and Yki-Järvinen, Hannele 2019. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight 4 (16) , e127902. 10.1172/jci.insight.127902

Publishers page: http://dx.doi.org/10.1172/jci.insight.127902

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



SUPPLEMENTARY MATERIAL FOR: Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids

Panu K. Luukkonen^{1,2,*}, Auli Nick^{1,3*}, Maarit Hölttä-Vuori^{1,3}, Christoph Thiele⁴, Elina Isokuortti^{1,2}, Susanna Lallukka-Brück^{1,2}, You Zhou^{1,5,6}, Antti Hakkarainen^{7,8}, Nina Lundbom⁷, Markku Peltonen⁹, Marju Orho-Melander¹⁰, Matej Orešič^{11,12}, Tuulia Hyötyläinen¹³, Leanne Hodson¹⁴, Elina Ikonen^{1,3,**,§}, Hannele Yki-Järvinen^{1,2,**,§}

¹Minerva Foundation Institute for Medical Research, Helsinki, Finland, ²Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ³Faculty of Medicine, Department of Anatomy, University of Helsinki, Helsinki, Finland, ⁴LIMES Institute, Bonn University, Bonn, Germany, ⁵Systems Immunity Research Institute, Cardiff University, Cardiff, UK, ⁶Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK, ⁷Department of Radiology, HUS Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ⁸Department of Neuroscience and Biomedical Engineering, Aalto University School of Science, Espoo, Finland, ⁹Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland, ¹⁰Department of Clinical Sciences, Lund University, Malmö, Sweden, ¹¹Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland, ¹²School of Medical Sciences, Örebro University, Örebro, Sweden, ¹³Department of Chemistry, Örebro University, Örebro, Sweden, ¹⁴Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK, *Authors share co-first authorship, **Authors share co-last authorship, § Corresponding Author.

LIPIDOMIC ANALYSIS

Sample preparation and chemicals

All solvents were HPLC grade or LC-MS grade, from Honeywell (Morris Plains, NJ, USA), Fisher Scientific (Waltham, MA, USA) or Sigma-Aldrich (St. Louis, MO, USA). Mass spectrometry grade ammonium acetate and reagent grade formic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Samples were extracted in random order as follows: 10 µL of 0.9% NaCl and, 120 µL of CHCl3: MeOH (2:1, v/v) containing internal standards (c= $2.5 \mu g mL$ -1) were added to 10 μL of each plasma sample. The standard solution contained the following compounds: 1,2-diheptadecanoyl-sngly¬cero-3-phosphoethanolamine (PE(17:0/17:0)), N-heptadecanoyl-D-erythrosphingosylphosphorylcho¬line N-heptadecanoyl-D-erythro-sphingosine (SM(d18:1/17:0)), (Cer(d18:1/17:0)),1,2-diheptadecanoyl-sn-glycero-3-phosphocholine (PC(17:0/17:0)), 1heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC(17:0)) and 1-palmitoyl-d31-2-oleoylsn-glycero-3-phosphocholine (PC(16:0/d31/18:1)), purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA), and tripalmitin- Triheptadecanoylglycerol (TG(17:0/17:0)) Larodan AB, Solna, Sweden). The samples were vortex mixed and incubated on ice for 30 min after which they were centrifuged (9400 \times g, 3 min). 60 µL from the lower layer of each sample was then transferred to a glass vial with an insert and 60 μ L of CHCl3: MeOH (2:1, v/v) was added to each sample. The samples were re-randomized and stored at -80 °C until analysis.

Calibration curves using 1-hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (PC(16:0e/18:1(9Z))), 1-(1Z-octadecenyl)-2-(9Z-octade¬cenoyl)-sn-glycero-3-phosphocholine (PC(16:0/16:0), 1-octadecanoyl-sn-glycero-3-phospho¬choline (LPC(18:0)), (LPC18:1), 1-2-dioleoyl-sn-glycerol ((DG(18:1/18:1)), (2-aminoethoxy)[(2R)-3-hydroxy-2-[(11Z)-octadec-11-enoyloxy]propoxy]phosphinic acid (LysoPE(18:1)), N-(9Z-octadecenoyl)-sphinganine (Cer

1-hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (PE (d18:0/18:1(9Z))), (16:0/18:1)) and 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1'myo-inositol)n (PI(18:0-20:4)) from Avanti Polar Lipids, Inc., 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphatidylcholine (LPC(16:0)) from Larodan, and 1.2.3 trihexadecanoalglycerol (TG16:0/16:0), 1,2,3 trioctadecanoalglycerol (TG(18:0/18:0)) and cholest-5-en-3β-yl octadecanoate (ChoE(18:0)), 3β-Hydroxy-5-cholestene-3-linoleate (ChoE(18:2)) from Larodan, were prepared prepared to the following concentration levels: 100, 500, 1000, 1500, 2000 and 2500 ng mL-1 (in CHCl3:MeOH, 2:1, v/v) including 250 ng mL-1 of each internal standard.

UHPLC-QTOFMS analysis

The UHPLC system used was 1290 Infinity system from Agilent Technologies (Santa Clara, CA, USA). The system was equipped with a multisampler (maintained at 10 °C) using 10% DCM in MeOH and ACN:MeOH:IPA:H₂O (1:1:1:1, v/v/v/v) + 0.1% HCOOH as needle wash solutions after each injection for 7.5 s each, a quaternary solvent manager and a column thermostat (maintained at 50 °C). Separations were performed in a ACQUITY UPLC® BEH C18 column (2.1 mm × 100 mm, particle size 1.7 µm) by Waters Corporation (Milford, MA, USA). The flow rate was 0.4 mL min⁻¹ and the injection volume was 1 µL. H₂O + 1% NH₄Ac (1M) + 0.1% HCOOH (A) and ACN:IPA (1:1, v/v) + 1% NH₄Ac + 0.1% HCOOH (B) were used as the mobile phases for the gradient elution. The gradient was as follows: from 0 to 2 min 35-80% B, from 2 to 7 min 80-100% B and from 7 to 14 min 100% B. Each run was followed by a 7 minute re-equilibration period under initial conditions (35% B).

The mass spectrometer used was a 6545 quadrupole time of flight (QTOF) instrument from Agilent Technologies (Santa Clara, CA, USA), interfaced with a dual jet stream electrospray (dual ESI) ion source. Nitrogen generated by a nitrogen generator (PEAK Scientific, UK) was used as the nebulizing gas at a pressure of 21 psi, as the drying gas at a flow rate of 10 L min⁻¹ (at 193 °C) and as the sheath gas at a flow rate of 11 L min⁻¹ (at 379 °C). Pure nitrogen (6.0) from AGA (Munich, Bavaria, Germany.) was used as the collision gas. The capillary voltage and the nozzle voltage were kept at 3643 V and 1500 V, respectively. The reference mass solution including ions at m/z 121.0509 and 922.0098 was prepared according to instructions by Agilent. The acquisition mass range was m/z 100-1700 and the instrument was run using the extended dynamic range with an approximate resolution of 30 000 FWHM measured on the ion at m/z 1521.9715 (which is included in the tune mixture) during calibration of the instrument. MassHunter B.06.01 software (Agilent Technologies, Santa Clara, CA, USA) was used for all data acquisition and MZmine 2 was used for data processing.

MS data processing was performed using open source software MZmine 2.33. The following steps were applied in the processing: 1.) Mass detection with a noise level of 750, 2.) Chromatogram builder with a min time span of 0.08 min, min height of 800 and a m/z tolerance of 0.006 m/z or 10.0 ppm, 3.) Chromatogram deconvolution using the local minimum search algorithm with a 70% chromatographic threshold, 0.05 min minimum RT range, 1% minimum relative height, 800 minimum absolute height, a minimum ration of peak top/edge of 1.2 and a peak duration range of 0.08 - 5.0, 4.), Isotopic peak grouper with a m/z tolerance of 6.0 ppm, RT tolerance of 0.05 min, maximum charge of 2 and with the most intense isotope set as the representative isotope, 5.) Peak list row filter keeping only peak with a minimum of 10% of the samples in a row, 6.) Join aligner with a m/z tolerance of 0.008 or 10.0 ppm and a weight for of 2, a RT tolerance of 0.1 min and a weight of 1 and with no requirement of charge state or ID and no comparison of isotope pattern, 7.) Gap filling using the same RT and m/z range gap filler algorithm with an m/z tolerance of 0.008 or 10 ppm, 8.) Identification of lipids using a custom database search with an m/z tolerance of 0.006 009 m/z or 10.0 ppm and a RT tolerance of 0.1 min, 9.) Normalization using internal standards (PE (17:0/17:0), SM (d18:1/17:0), Cer (d18:1/17:0), LPC (17:0), TG (17:0/17:0/17:0) and PC (16:0/d30/18:1)) for

identified lipids and closest ISTD for the unknown lipids 10). The concentrations were calculated using lipid-class based concentration curves.

Generation of stable A431 cell lines expressing GFP-tagged PNPLA3-148I and PNPLA3-148M proteins

GFP-PNPLA3-148I and GFP-PNPLA3-148M encoding PCR fragments were inserted into the pSH-EFIRES vector (kind gift from Shiqian Li) encoding a puromycin selection cassette, EF1alpha promoter and AAVS1 homology arms. The constructs were then transfected to A431 PNPLA3-ko cells for integration into the AAVS1/Safe Harbor locus, and the cells were cultured under puromycin selection (1 μ g/ml).

SUPPLEMENTAL FIGURES AND FIGURE LEGENDS



Figure S1. Concentrations of ¹³C-labeled fatty acids in (A-B) plasma chylomicron-TG, (C-D) free fatty acids and (E-F) VLDL-TG in the PNPLA3^{148MM} and PNPLA3^{148II} groups during the postprandial period. Data are shown as mean±SEM. The blue lines and circles denote the PNPLA3^{148II} (n=14) group and the red lines and squares the PNPLA3^{148MM} (n=12) group. There were no significant differences between the groups as determined using 2-way ANOVA.



Figure S2. Expression level and lipid droplet association of GFP-tagged PNPLA3-148I and PNPLA3-148M proteins in A431 cells. (A) Western blotting of GFP-tagged PNPLA3-148I and PNPLA3-148M proteins stably expressed on PNPLA3-ko A431 cell background. Cell lysates (30 μg protein) were immunoblotted using anti-GFP (Abcam ab290) or anti-PNPLA3 (Santa Cruz) antibodies. (B) PNPLA3-ko cells expressing GFP-tagged PNPLA3-148I or PNPLA3-148M proteins were incubated for 50 min with 200 μM oleic acid, then fixed and stained with the lipid droplet dye LD540. Please note the more prominent localization of PNPLA3-148M on LDs compared to PNPLA3-148I.



Figure S3. Partitioning of alkyne-labeled linoleate in different lipid species in A431 cells during lipolysis. (A) A431 PNPLA3-148I cells were labeled for 1h min with 100 μM alkyne-linoleate in the presence of a cholesterol esterification inhibitor. After labeling, cells were either harvested (0 min chase) or further incubated in lipoprotein-deficient medium supplemented with cholesterol esterification and DGAT inhibitors for the indicated times before collecting. Cells were extracted,

click-reacted and analysed by TLC. Bars: % of alkyne-linoleate in indicated lipid species \pm SD, representative experiment in duplicate. (B) Homozygous PNPLA3-148I, PNPLA3-148M-ki and PNPLA3-ko A431 cells were labeled and incubated as in (A). Bars: % of incorporated alkyne-linoleate in PC, normalized to PNPLA3-148I cells at 0 min chase \pm SEM. N=5-8 from 3-4 individual experiments.

	PNPLA3 ¹⁴⁸¹¹	PNPLA3 ^{148MM}
Accelerometer data		
Accelerometer wear time (min/day)	773 (692 – 847)	799 (728 – 887)
Steps (n/day)	8957 (7220 – 9962)	8473 (4896 – 11023)
Sedentariness (% of wear time)	58 (57 - 63)	64 (57 - 70)
Light activity (% of wear time)	34 (29 - 38)	28 (26 - 40)
Moderate activity (% of wear time)	7 (5 – 8)	4 (2 – 10)
Sitting time (min/day)	378 (310 - 486)	389 (323 - 546)
Sitting periods >30min (n)	14 (11 – 19)	14 (10 – 36)
Food record data		
Energy intake (kcal/day)	2000 (1611 - 2398)	2033 (1523 – 2220)
Protein intake (E%)	16.6 (12.9 – 21.4)	17.1 (15.2 – 20.6)
Carbohydrate intake (E%)	41.6 (34.0 - 50.3)	42.7 (37.3 – 44.7)
Fat intake (E%)	37.4 (32.8 – 45.1)	37.8 (32.5 - 39.5)
Saturated fat intake (E%)	10.9 (9.7 – 16.0)	12.1 (10.5 - 14.1)
Monounsaturated fat intake (E%)	12.8 (11.6 – 17.4)	13.9 (11.2 – 15.2)
Polyunsaturated fat intake (E%)	7.0 (6.5 – 8.2)	6.7 (5.6 – 8.6)
Total fibre intake (g/day)	20.9 (17.0 – 31.3)	19.3 (13.4 – 24.5)
Data are in median (25th-75th percentile). The differences in variables between the groups were compared using Mann Whitney U test. There were no significant differences in any		

variable. E%, energy percent.

Table S1. Physical activity measured using an accelerometer and dietary intake based on food record data of the PNPLA3^{148MM} and PNPLA3^{148II} groups.